Aviva PLC Purchases 38,765 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Aviva PLC raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 39.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 137,413 shares of the biopharmaceutical company's stock after purchasing an additional 38,765 shares during the quarter. Aviva PLC owned 0.11% of Halozyme Therapeutics worth $6,570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. HighTower Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 20.2% in the 3rd quarter. HighTower Advisors LLC now owns 36,174 shares of the biopharmaceutical company's stock worth $2,080,000 after purchasing an additional 6,075 shares in the last quarter. Stifel Financial Corp boosted its stake in Halozyme Therapeutics by 126.3% in the third quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company's stock worth $980,000 after buying an additional 9,555 shares in the last quarter. EP Wealth Advisors LLC bought a new position in Halozyme Therapeutics during the third quarter valued at approximately $357,000. MML Investors Services LLC raised its stake in shares of Halozyme Therapeutics by 80.7% during the third quarter. MML Investors Services LLC now owns 9,779 shares of the biopharmaceutical company's stock worth $560,000 after acquiring an additional 4,366 shares in the last quarter. Finally, M&T Bank Corp lifted its holdings in shares of Halozyme Therapeutics by 0.5% in the 3rd quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company's stock worth $6,367,000 after acquiring an additional 561 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Remove Ads

Halozyme Therapeutics Trading Up 0.6 %

Shares of HALO traded up $0.34 during trading hours on Monday, reaching $60.56. 113,739 shares of the company traded hands, compared to its average volume of 1,406,851. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $66.00. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of 17.66, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company's fifty day moving average price is $60.22 and its two-hundred day moving average price is $54.91. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HALO. Benchmark reiterated a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $62.78.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.